Body Mass Index in Relation to Prostate-specific Antigen-related Parameters

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2021 Sep 17

PMID 34530776

Authors

Dandan Lin

Ting Liu

Luling Chen

Zongtao Chen

Affiliations

Soon will be listed here.

Abstract

Background: Only a few previous studies conducted to assess the association between body mass index (BMI) and prostate-specific antigen (PSA) related parameters have taken prostate volume (PV) and blood volume (BV) into consideration. The objective of this study was to assess the relationship between BMI and parameters of PSA concentrations in Chinese adult men.

Methods: A total of 86,912 men who have received annual physical examination at the First Affiliated Hospital of Army Medical University from 1 January 2011 to 31 December 2018 were included in this study. Linear regression models were performed to assess the relationship between BMI, PV, BV and PSA, and analyze the correlation between BMI and PSA, PSA density and PSA mass.

Results: The univariable linear regression showed that PV, BV, systolic pressure (SBP), pulse, fasting blood glucose (FBG) and age were significantly associated with PSA level (P < 0.05). The multivariate linear regression demonstrated that PV, BV, FBG and age were significantly associated with PSA level (P < 0.05). WHR and BMI is negatively associated with PSA and PSA density (P < 0.05), and no statistically significant association was found between PSA mass and WHR and (P = 0.268) or BMI (P = 0.608).

Conclusions: The findings of this large-sample, hospital-based study in China indicate that PV was positively associated with serum PSA concentrations, while BMI and BV were inversely related with PSA levels. PSA mass can be used to estimate the PSA concentration without being affected by obesity in Chinese men.

References

Fowke J, Matthews C . PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate. 2009; 70(2):120-5. PMC: 2798924. DOI: 10.1002/pros.21039. View

Giovannucci E, Rimm E, Chute C, Kawachi I, Colditz G, Stampfer M . Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994; 140(11):989-1002. DOI: 10.1093/oxfordjournals.aje.a117206. View

Dunn M . Prostate Cancer Screening. Semin Oncol Nurs. 2017; 33(2):156-164. DOI: 10.1016/j.soncn.2017.02.003. View

Martinez-Pineiro L, Garcia Mediero J, Gonzalez Gancedo P, Tabernero A, Lozano D, Lopez-Tello J . Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml. World J Urol. 2004; 22(2):124-31. DOI: 10.1007/s00345-003-0393-5. View

Bonn S, Sjolander A, Tillander A, Wiklund F, Gronberg H, Balter K . Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer. 2016; 139(1):50-7. DOI: 10.1002/ijc.30052. View

Price M, Hamilton R, Robertson C, Butts M, Freedland S . Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008; 71(5):787-91. DOI: 10.1016/j.urology.2007.11.036. View

Walsh P . The association of body mass index and prostate-specific antigen in a population-based study. J Urol. 2005; 174(5):1825. View

Yelsel K, Alma E, Eken A, Gulum M, Ercil H, Ayyildiz A . Effect of obesity on International Prostate Symptom Score and prostate volume. Urol Ann. 2015; 7(3):371-4. PMC: 4518378. DOI: 10.4103/0974-7796.152056. View

Sarma A, Jaffe C, Schottenfeld D, Dunn R, Montie J, Cooney K . Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology. 2002; 59(3):362-7. DOI: 10.1016/s0090-4295(01)01546-1. View

10.

. All Cancers Estimated Incidence, Mortality and Prevalence of All Cancers (excluding non-melanoma skin cancer) in 2012. J Natl Cancer Inst. 2017; 109(9). DOI: 10.1093/jnci/djx205. View

11.

Yang H, Doo S, Yang W, Song Y . Which obesity index best correlates with prostate volume, prostate-specific antigen, and lower urinary tract symptoms?. Urology. 2012; 80(1):187-90. DOI: 10.1016/j.urology.2012.04.003. View

12.

Loeb S, Carter H, Schaeffer E, Ferrucci L, Kettermann A, Metter E . Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol. 2009; 182(6):2646-51. PMC: 4197054. DOI: 10.1016/j.juro.2009.08.041. View

13.

Banez L, Hamilton R, Partin A, Vollmer R, Sun L, Rodriguez C . Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007; 298(19):2275-80. DOI: 10.1001/jama.298.19.2275. View

14.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

15.

Grubb 3rd R, Black A, Izmirlian G, Hickey T, Pinsky P, Mabie J . Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):748-51. DOI: 10.1158/1055-9965.EPI-08-0938. View

16.

Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate A, Fabbri R . Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991; 40(1):101-4. DOI: 10.1016/0026-0495(91)90199-7. View

17.

Catalona W, Smith D, Ratliff T, Dodds K, Coplen D, Yuan J . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156-61. DOI: 10.1056/NEJM199104253241702. View